IGC Pharma Inc (IGC)
0.466
+0.01
(+2.06%)
USD |
NYAM |
Apr 24, 10:29
IGC Pharma Enterprise Value: 27.86M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 27.86M |
| April 22, 2024 | 27.13M |
| April 19, 2024 | 29.99M |
| April 18, 2024 | 29.10M |
| April 17, 2024 | 36.14M |
| April 16, 2024 | 29.73M |
| April 15, 2024 | 26.75M |
| April 12, 2024 | 26.81M |
| April 11, 2024 | 32.54M |
| April 10, 2024 | 32.60M |
| April 09, 2024 | 35.41M |
| April 08, 2024 | 38.28M |
| April 05, 2024 | 40.16M |
| April 04, 2024 | 42.73M |
| April 03, 2024 | 39.58M |
| April 02, 2024 | 32.89M |
| April 01, 2024 | 29.10M |
| March 28, 2024 | 24.25M |
| March 27, 2024 | 24.67M |
| March 26, 2024 | 24.19M |
| March 25, 2024 | 24.25M |
| March 22, 2024 | 22.72M |
| March 21, 2024 | 20.43M |
| March 20, 2024 | 20.72M |
| March 19, 2024 | 22.86M |
| Date | Value |
|---|---|
| March 18, 2024 | 20.37M |
| March 15, 2024 | 19.44M |
| March 14, 2024 | 20.20M |
| March 13, 2024 | 19.98M |
| March 12, 2024 | 19.48M |
| March 11, 2024 | 19.95M |
| March 08, 2024 | 19.99M |
| March 07, 2024 | 19.79M |
| March 06, 2024 | 19.69M |
| March 05, 2024 | 20.13M |
| March 04, 2024 | 21.00M |
| March 01, 2024 | 21.07M |
| February 29, 2024 | 20.72M |
| February 28, 2024 | 21.00M |
| February 27, 2024 | 20.57M |
| February 26, 2024 | 21.00M |
| February 23, 2024 | 18.07M |
| February 22, 2024 | 15.97M |
| February 21, 2024 | 16.66M |
| February 20, 2024 | 17.36M |
| February 16, 2024 | 17.88M |
| February 15, 2024 | 17.66M |
| February 14, 2024 | 17.63M |
| February 13, 2024 | 17.57M |
| February 12, 2024 | 17.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-3.279M
Minimum
Mar 18 2020
138.25M
Maximum
Feb 10 2021
30.42M
Average
19.69M
Median
Mar 06 2024
Enterprise Value Benchmarks
| CEL-SCI Corp | 76.11M |
| AIM ImmunoTech Inc | 8.852M |
| NovaBay Pharmaceuticals Inc | 2.275M |
| Protalix BioTherapeutics Inc | 63.35M |
| Palatin Technologies Inc | 18.75M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.589M |
| Revenue (Quarterly) | 0.204M |
| Total Expenses (Quarterly) | 3.202M |
| EPS Diluted (Quarterly) | -0.09 |
| Gross Profit Margin (Quarterly) | 65.20% |
| Profit Margin (Quarterly) | -2.74K% |
| Earnings Yield | -55.79% |
| Normalized Earnings Yield | -46.96 |